In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
High level results on datopotamab raise safety and efficacy concerns, putting billion-dollar sales forecasts at risk.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
The search is on for signals in front-line use, where Daiichi Sankyo and Astrazeneca have already bet big with the Trop2-targeted project.
Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.
In Trop2 Merck & Co might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.